



Pneumonia remains the leading global cause of death among children under age five, killing more 
than 900,000 children in 2013 and accounting for 15% of all child deaths [1]. Streptococcus 
pneumoniae (pneumococcus) is the most common cause of severe pneumonia. Pneumococcus also 
causes sepsis and meningitis and is one of the leading causes of bacterial otitis media (OM). In 
addition, pneumococci cause significant morbidity and mortality in elderly adults.   
There are two main limitations of the currently available pneumococcal vaccines that are based on 
polysaccharide antigens. Firstly, despite a clear overall benefit of polysaccharide conjugate vaccines 
(PCVs), increasing pneumococcal disease caused by non-vaccine serotypes, through serotype 
emergence or replacement, has been well documented in many countries where PCVs have been 
used for several years [2]. The introduction of PCVs covering additional serotypes (PCV-10 and PCV-
13) has helped to reduce serotype replacement in the short term [3]. The issue of serotype 
replacement is potentially of particular relevance for low-income countries where there is a broader 
spectrum of serotypes that cause disease [4, 5]. Secondly, PCVs are difficult to manufacture and 
therefore relatively expensive, which, without considerable financial assistance, limits their 
affordability and accessibility for low-income countries [6].  
Pneumococcal vaccines that are more affordable and provide either protection against serotypes 
prevalent in the developing world or, ideally, broad protection across all pneumococcal serotypes 
would be highly desirable. A relatively new approach is to move away from using polysaccharide 
antigens to target conserved surface proteins common to most or all pneumococcal strains.  One 
conserved protein, the cholesterol-binding haemolytic cytotoxin pneumolysin (Ply), is closely 
associated with the development of invasive disease and inflammation [7]. Non-toxic Ply mutants 
have been shown to give protection in animal models [8]. The most advanced protein vaccine 
candidates, including combinations of recombinant antigens and killed whole cell preparations, have 
been tested clinically, including Phase 2 trials in infants and elderly adults [9, 10]. By their nature 
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these vaccines have multiple mechanisms of action and the effect on nasopharyngeal colonisation is 
under investigation in regions of high carriage rates in Africa [11] and Asia.  
The objective of this Phase 1 trial was to investigate in adults the safety and immunogenicity of a 
new, novel pneumococcal vaccine at 3 dose levels. PnuBioVax®, described in this manuscript, is a 
vaccine produced from genetically-modified S. pneumoniae TIGR4 in whom the Ply gene has been 
mutated to remove toxicity whilst retaining immunogenicity [12]. The bacteria are subjected to 
stress during fermentation, induced by a temperature shift from 30°C to 37°. This temperature shift 
is designed to mimic the translocation of S. pneumoniae from the nasopharynx to the circulatory 
system and from a commensal to an invasive phenotype thereby upregulating proteins that may be 
relevant for provoking protective immune responses as a consequence of infection. Following 
detergent extraction and ion exchange chromatography, the final vaccine includes multiple protein 
antigens, including PspA and non-toxic Ply and is formulated without additional adjuvant. PnuBioVax 
is under development as a vaccine against S. pneumoniae infection and offers the potential for 
broad-based protection against a wide range of pneumococcal strains and lower production costs 
compared to PCVs. 
2. METHODOLOGY 
2.1 Study vaccine  
PnuBioVax is a sterile liquid formulated in 40 mM Tris, 150 mM NaCl, pH 8.0 at a protein 
concentration of 1 mg/mL. For 50 and 200 µg dose levels, the vaccine (PnuBioVax: Batch 15100) was 
diluted with 40 mM Tris, 150 mM NaCl, pH 8.0 prior to administration. This diluent also served as the 
placebo. PnuBioVax is non-adjuvanted. Vaccine and placebo were administered at a 0.5 mL volume 
by intramuscular injection. The trial was performed at a single site, Simbec Research Limited. 
2.2 Study participants & study design 
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The trial (SPV-001) was a first-in-human randomised, placebo-controlled, parallel group, double-
blind, dose escalation trial to evaluate the safety and immunogenicity of PnuBioVax administered on 
three occasions 28 days apart, at 50, 200 and 500 µg in adult subjects. Thirty six  healthy males and 
females, aged 18 to 40 years, were recruited and divided into three cohorts of 12 subjects (9 
receiving PnuBioVax and 3 placebo). Subjects were allocated to treatment groups according to a 
randomisation code using the PROC PLAN procedure of SAS® version 9.1.3.  
After the first dose and at pre-determined times on each dosing day and follow-up visit, a safety 
review was conducted for dose escalation purposes. Dose escalation only proceeded following 
satisfactory review of the blinded day 8 safety data that included adverse events (AEs), routine 
laboratory assessments, vital signs, lymph node assessment, injection site reactions and concomitant 
medication from at least 9 evaluable subjects in the preceding cohort. 
All subjects received at least one PnuBioVax or placebo dose and these constitute the safety 
population. Prior to unblinding, protocol deviations were identified in 7 subjects that were 
considered likely to affect the scientific interpretation of immunogenicity data. Therefore the 
immunogenicity analysis is based on the per protocol population (29 subjects). 
The trial protocol and all relevant amendments, together with subject information and consent 
documents were reviewed and approved by Wales Research Ethics Committee 2. Clinical Trials 
Authorisation was obtained from the Medicines and Healthcare Regulatory Agency (MHRA). The 
clinical trial was performed in accordance with the Declaration of Helsinki (Brazil, 2013) and the 
principles of Good Clinical Practice. 
2.3 Safety and reactogenicity assessment 
The primary assessment was based on the incidence and severity of all treatment emergent adverse 
events (TEAEs). Secondary assessments were (i) The incidence and severity of common systemic 
vaccine related AEs (anorexia, nausea/vomiting, diarrhoea, headache, fatigue, myalgia, fever); (ii) 
The incidence and severity of injection site reactions (pain, tenderness, erythema, induration, 
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pruritus); and (iii) Changes in laboratory parameters (biochemistry, haematology and urinalysis) or 
physical examination from day 1 (baseline) to day 64 that were considered to be clinically significant. 
2.4 Immunogenicity assessment 
2.4.1 Anti-PnuBioVax IgG  
Sera were prepared from blood samples taken on days 1 (pre-dosing), 29 (post dose 1), 57 (post 
dose 2) and 85 (post dose 3) to assess IgG antibody responses by ELISA. The assay was qualified and 
conducted by Simbec Research. Briefly, 96-well plates were coated with PnuBioVax, washed, and 
incubated with serially diluted duplicate samples of test serum. Bound antibody was detected with 
peroxidase-conjugated donkey anti-human IgG and developed with TMB. Absorbance values were 
plotted against the reciprocal value of the serum dilution, using a 4 parametric logistic regression 
with a semi-logarithmic scale to obtain titration curves for each sample. The end-point titre was 
determined as the titre where the absorbance was equal to a pre-determined cut-point of 0.5. 
The proportion of subjects who developed an immune response to PnuBioVax were determined. An 
immune response was defined in two ways. Firstly, as at least a 2 fold increase in antibody titre from 
the baseline. Secondly, to compare the change in immune responses in PnuBioVax immunised 
subjects with any change observed in placebo subjects at the same time point.  A response was 
defined as a change that was ≥2 x standard deviation (SD) of the placebo change at the same time 
point.  
2.4.2 Multiplexed electrochemiluminescence (ECL) assay using MSD technology 
This exploratory investigation measured antibody production against specific pneumococcal proteins 
at days 1 and 85. This procedure was conducted at UCL (University College London) GOS Institute of 
Child Health, London and utilises MesoScale Discovery (MSD, Rockville, MD, USA). The serum IgG 
antibodies to pneumococcal protein antigens were measured using a direct binding 
electrochemiluminescence- based multiplex assay [13] on customised 8 antigen plates. Antibody 
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interaction with immobilised recombinant antigen was converted into ECL signal and read using an 
ECL detector. ECL signal is relative to antibody concentration.  
2.4.3 Ply neutralisation assay 
The ability of anti-Ply antibodies, raised against the non-toxic Ply, to inhibit haemolysis was also 
investigated. Samples containing antibody were serially diluted and added to a lysate prepared from 
whole S. pneumoniae (WT) TIGR4 which has been subjected to multiple rounds of freeze/thawing. 
Lysates were also prepared from S. pneumoniae 6B and 11A. Lysates, which contains native Ply, was 
first titrated to obtain a dilution at which maximum lysis of a fixed number of red blood cells (RBC) 
was achieved. IgG prepared from human sera samples was incubated in the presence of the lysate 
(at the selected concentration) and then added to RBC and incubated. Plates were centrifuged to 
pellet the remaining RBC and supernatant transferred to a 96 well plate and absorbance (OD450) 
measured. Sera concentration was plotted against absorbance and an end-point titre, defined as 
50% inhibition of the maximum lysis, obtained.  
2.5 Statistical methods 
AEs were coded using Medical Dictionary for Regulatory Activities (MedDRA) version 18.1.  The 
incidence of TEAE and vaccine-related TEAEs was summarised by organ system, preferred term, 
severity and relationship to study drug.  Abnormal laboratory safety, vital signs and 12-lead ECG data 
were tabulated.  Absolute and change from baseline haematology, biochemistry and vital signs 
parameters were summarised descriptively. Lymph node and injection site reaction assessments 
were also summarised by frequency for each category.  
Anti-PnuBioVax IgG titre responses were summarised descriptively and a comparison between 
treatments carried out using an analysis of covariance (ANCOVA) model with fixed effect for 
treatment and the log transformed baseline as a covariate. Fold increase in antibody titres were 
summarised and a ratio of the geometric means between the baseline and post-baseline visit 
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calculated.  A comparison of the mean fold increase was carried out between treatments using an 
analysis of variance (ANOVA) model with fixed effect for treatment.  Adjusted least squares means 
(LS Means) from the ANOVA model were also calculated, along with the 95% confidence intervals 
(CI). 
From the fold increase in antibody titres, the proportion of subjects who developed an immune 
response to PnuBioVax, were summarised by frequency for each response category. 
Ply neutralisation titres were compared between treatments using the fold increase in titre between 
day 85 and baseline samples for each subject and summarised by frequency. 
3. RESULTS 
3.1 Study participants 
Subject demographics are summarised in Table 1. Of note is the higher percentage of male 
compared to female volunteers enrolled in the trial. 
Table 1 Subject demographics 
 
 
3.2 Safety and reactogenicity 
In 36 subjects, there were a total of 87 TEAEs in the PnuBioVax and placebo groups (Table 2), 
including 31 that were classified as common vaccine-related AEs. There were no serious AEs. The 
common vaccine-related AEs occurred in 13 PnuBioVax (48%) and 2 placebo (22%) subjects.  





The most commonly occurring TEAE was headache.  This was the only TEAE classified as a common 
systemic vaccine related TEAE that was reported (Table 3). When the number of subjects reporting 
any TEAE was compared, a higher % of subjects reported TEAEs following PnuBioVax when 
compared to placebo (21 (77.8%) vs 6 (66.7%), with a tendency towards an increase in the incidence 
of moderate headache with increasing dose of PnuBioVax (0 (0.0%), 2 (22.0%), 3 (33.3%) and 5 
(55.6%) for placebo, 50, 200 and 500 µg PnuBioVax, respectively), although the majority were 
considered unlikely to be or unrelated to the vaccine. When the number of subjects reporting any 
TEAE was compared, a higher % of subjects reported TEAEs following PnuBioVax when compared to 
placebo (21 (77.8%) vs 6 (66.7%) with a tendency towards an increase in the incidence of moderate 
headache with increasing dose of PnuBioVax (0 (0.0%), 2 (22.0%), 3 (33.3%) and 5 (55.6%) for 
placebo, 50, 200 and 500 µg PnuBioVax, respectively), although the majority were considered 
unlikely to be or unrelated to the vaccine. 
Table 3 Common vaccine related AEs 
 
Injection site reactions (mostly pain and tenderness graded mild or moderate) were commonly 
reported, in particular in the 200 µg and 500 µg PnuBioVax groups. 2 subjects withdrew on the basis 
of moderate or severe reactions.  
Across the entire assessment period (days 1 - 64), a higher number of subjects who received 
PnuBioVax reported pain (25 (92.6%) vs 4 (44.4%)) and tenderness (22 (81.5%) vs 1 (11.1%)) when 
compared to placebo. The pain and tenderness was mostly mild in intensity (grade 1) in that it did 
not interfere with activity and caused mild discomfort to touch.  






On each dosing day, there appeared to a delayed onset in pain and tenderness, with higher % 
subjects reporting pain and tenderness at 4, 8 and 20 hours post-dose when compared to 1 and 
2 hours post-dose. Moderate (grade 2) pain and tenderness was reported by 4 (14.8%) subjects who 
received PnuBioVax, 2 (22.2%) following 200 µg and 2 (22.2%) following 500 µg. By day 7 post each 
dose, all reactions reported as moderate had subsided with the exception of one subject who 
recorded moderate pain and tenderness on day 29, which progressed to severe on day 31 resulting 
in them being withdrawn from the trial.  
No subject reported any severe (grade 3) or potentially life threatening (grade 4) injection site 
reactions at their scheduled visits.  
Across the entire assessment period (days 1 - 64), the incidence of erythema, induration and 
swelling was low, with 2 (7.4%) subjects who received PnuBioVax reporting mild transient erythema, 
both after 500 µg and 4 (11.1%) subjects reporting mild induration and swelling, of which 1 (11.1%) 
received placebo and 3 (11.1%) received 500 µg PnuBioVax.  No subject reported any moderate 
(grade 2), severe (grade 3) or potentially life threatening (grade 4) erythema or induration and 
swelling following PnuBioVax or placebo. No subject reported pruritus at the injection site following 
PnuBioVax or placebo. 
There were no vaccine related clinically significant changes in biochemistry, physical examination, 
lymph node assessment, vital signs or 12 lead ECG parameters during the trial.  
3.3 Immunogenicity 
3.3.1 Anti-PnuBioVax IgG titres 
32 subjects received 3 immunisations of which 29 were considered ‘per-protocol’ prior to 
unblinding. Total IgG response to PnuBioVax was measured by ELISA. For the per protocol 
population, IgG endpoint titres are presented as geometric mean concentrations (with 95% 
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confidence intervals) for groups at days 1 (baseline), 29, 57 and 85 (Table 5). As expected, significant 
baseline titres were found in the adult subjects and therefore data were analysed by comparing 
titres post- and pre-immunisation as a ratio (fold increases). In addition, the number of subjects in 
each group achieving an immune response, as defined in Methodology, is reported (Table 5). 
The fold-increase was statistically significantly higher for 200 and 500 µg PnuBioVax vs 50 µg 
PnuBioVax and placebo at each timepoint post-immunisation. Comparing with placebo at day 85, p 
values for the 200 and 500 µg groups were 0.0004 and <0.0001, respectively. There was no evidence 
of a difference in fold-increase between 200 and 500 µg PnuBioVax or 50 µg PnuBioVax and placebo. 
Combining the 200 and 500 µg groups, 12 (100%) and 11 (91.7%) subjects who received PnuBioVax 
exhibited a fold increase in IgG titre of ≥2 SD of placebo on days 57 (after 2 doses) and 85 (after 3 
doses). Similarly in these groups, 3 (25%) and 7 (58.3%) subjects exhibited a ≥2 fold increase in IgG 
titre on days 57 and 85.  
Table 5 IgG response to PnuBioVax in per-protocol population 
 
 
3.3.2 Antibody responses against pneumococcal proteins 
29 subjects were evaluated in the per protocol population. Antibody responses against 
pneumococcal antigens PspA, Ply, PsaA, PiaA, the pilus proteins RrgB and RrgA were measured by 
MSD assays (Table 6). 
All subjects in PnuBioVax 50, 200 and 500 g dose groups had increases of ≥2 fold against the 
vaccine type pilus proteins RrgBT4 and RrgAT4 (TIGR4 protein sequences). Strong responses were 
also seen against the heterologous non-vaccine type pilus protein RrgB6B (serotype 6B protein 
sequence). Greater than 50% of subjects in the 200 and 500 g dose groups (n=12) achieved a ≥2 
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fold increase in ECL signal against the antigens PspA2 (family 2 protein sequence), Ply and PiaA, and 
5 out of 12 had responses against the PsaA protein.  
Table 6 Antibody responses against pneumococcal proteins.  
 
 
The number of subjects achieving a ≥2 fold increase from day 1 (baseline) to day 85 in antibody titres 
against individual pneumococcal proteins by ECL assay. 
3.3.3 Ply neutralisation 
Anti-Ply antibodies were purified and analysed to confirm functional activity in the haemolysis 
inhibition assay. Results using the TIGR4 lysate are shown in Table 7. In the 200 and 500 g groups 
(n=12), 50% of subjects achieved a ≥2 fold increase in endpoint titre (defined as 50% inhibition of 
haemolysis); in comparison, in the placebo group (n=9), no subjects recorded an increase of ≥2 fold 
from baseline levels. Using antibodies from subjects in the 200 g group, the same levels of 
Inhibition of haemolysis by lysates prepared from S.pneumoniae 6B and 11A were obtained. 





In this first investigation PnuBioVax in humans, the vaccine was considered safe and well tolerated 
following intramuscular injection of 50, 200 or 500 µg on 3 occasions to healthy adult subjects.  
There was a tendency towards more frequent and more severe injection site reactions with higher 
doses and an increased incidence of headache as the dose increased. Of particular note was the 
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absence of other typical vaccine-related adverse events such as anorexia, nausea/vomiting, 
diarrhoea, fatigue, myalgia (non-injection site) or fever. It can be concluded that vaccine safety 
would not preclude clinical investigation of PnuBioVax in target populations. 
The antibody titre data demonstrated measurable IgG (specific for PnuBioVax) pre-dose at baseline.  
In adults this was predicted and is the result of previous exposure to S. pneumoniae both as infants 
during the acquisition of natural immunity and continued exposure into adulthood. Titres at 28 days 
following the final PnuBioVax immunisation were used to calculate the fold increase to account for 
the varying baseline titres. In the small subject numbers in this trial, results indicated that significant 
increases in IgG titres were achieved at the 200 and 500 µg dose levels. In contrast to 
polysaccharide-based pneumococcal vaccines, there is no definition of a protective immune 
response for novel protein-based vaccines, such as PnuBioVax.  
Post-immunisation results demonstrate increases in antibody levels against several pneumococcal 
antigens. Importantly, antibodies against the non-toxic Ply were capable of neutralising the 
haemolytic activity of native Ply derived from several pneumococcal strains. There is evidence that 
neutralization of circulating Ply in mice can significantly attenuate cardiac injury during invasive 
pneumococcal disease (IPD) [14]. 
A multi-antigen vaccine such as PnuBioVax may be effective in several modes of action. Antibodies 
directed against ABC transporter pneumococcal proteins, PiaA and PsaA, have the potential to 
interfere with nutrient uptake [15, 16], whereas antibodies against the pilus proteins, RrgB and RrgA, 
may block adhesion [17, 18]. The role of PspA is to inhibit complement deposition on the 
pneumococcal surface and therefore antibodies to PspA may promote the opsonisation and killing of 
pneumococci [19].  
Healthy adults are not generally susceptible to IPD and there are several lines of evidence that this 
protection is provided by naturally acquired IgG against protein antigens and not, as previously 
thought, largely dependent on antibodies against capsular polysaccharide antigens [20]. The young 
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healthy population in this trial had significant baseline IgG against protein antigens present in 
PnuBioVax and this response was boosted by PnuBioVax immunisation. As the main target group for 
a broadly protection pneumococcal vaccine is the paediatric population with low natural immunity, 
the immunogenicity provided by PnuBioVax in this group requires investigation in Phase 2 studies. 
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